ArticleEuropean journal of medical research2025
Correlation of contrast-enhancing tumor region on pre-radiotherapy MRI with overall survival in glioblastoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRI semantic features as prognostic indicators and biological mechanism insights in glioblastoma multiforme.Neurosurgical review · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimHeterogeneity assessment of contrast-enhancing tumor regions on pre-radiotherapy magnetic resonance imaging (MRI) holds prognostic significance in glioblastoma (GBM), given its association with tumor progression and overall survival (OS). This study aimed to evaluate the prognostic value of radiomic features extracted from contrast-enhancing tumor regions on pre-radiotherapy MRI across multiple imaging sequences.
methodsA total of 74 GBM patients from The Cancer Imaging Archive were analyzed and categorized into short- and long-term survival groups based on their median survival of 18.8 months. Radiomic features were extracted from original, wavelet-filtered images, and Laplacian of Gaussian (LoG)-filtered images both individually and in combination across four MRI sequences: T1-weighted contrast-enhanced (T1WCE), T1W, T2-weighted (T2W), and fluid-attenuated inversion recovery (FLAIR). Feature selection was conducted using least absolute shrinkage and selection operator (Lasso) and radiomic scores (Rad-scores) were constructed. The capability of Rad-scores in stratifying OS was evaluated using receiver operating characteristic (ROC) and calibration curve analyses, along with Kaplan-Meier survival analysis. Furthermore, clinical characteristics were integrated to determine whether this combination enhanced the stratification performance.
resultsROC curve analysis of the Rad-scores demonstrated that wavelet features markedly improved performance compared to the combination of original and LoG features (AUC: 0.90 [0.81-0.96] vs. 0.83 [0.72-0.90]; BH-adjusted p = 0.0183) in differentiating between short- and long-term survivors. Combining wavelet and LoG-filtered features significantly improved survival stratification, outperforming the combination of original and LoG features (AUC: 0.92 [0.84-0.97] vs. 0.83 [0.70-0.90]; BH-adjusted p = 0.0229). Additionally, Kaplan-Meier survival analyses and log-rank tests further confirmed significant correlations between all radiomic feature groups and OS. Integrating clinical characteristics did not notably enhance the discriminatory power (p > 0.05). All the Rad-scores and the combined Rad-sores with clinical data, revealed good agreement between the predicted and actual OS probabilities (p > 0.05), except for the combination of original and LoG features and wavelet features with clinical characteristics (p
conclusionRadiomic analysis of contrast-enhancing tumors on pre-radiotherapy MRI sequences provides strong prognostic insights in GBMs. These findings demonstrate the potential of integrating wavelet-filtered radiomic features for risk stratification; prospective validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.